Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer
Ovarian cancer is associated with high mortality due to presentation at advanced stage and high recurrence following treatment with chemotherapy. Most of the prognostic variables in ovarian cancer, including stage and residual disease, are amenable for assessment only after surgery. Currently there are no established preoperative markers including, CA-125, that can predict overall survival in patients with ovarian cancer. The aim of our study was to evaluate the prognostic significance of the preoperative haematological markers platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) in patients with ovarian cancer.
Preoperative PLR and NLR were evaluated in 235 patients undergoing surgery for ovarian cancer. The prognostic significance of both markers was then determined by both uni- and multivariate analytical methods.
High preoperative PLR (p<0.001) and NLR (p=0.001) were significantly associated with poor survival using univariate Cox survival analysis. The median overall survival in patients with a PLR of <300 was 37.4 months (95%CI 26.1–48.7) and 14.5 months (95%CI 11.7–17.2) in those with a PLR of >300. PLR (p=0.03) but not NLR (p=0.575) retained its significance as a prognostic marker on multivariate Cox’s regression analysis, along with stage (p<0.001) and residual disease (p=0.015).
We have shown for the first time that PLR is a novel independent prognostic marker in patients with ovarian cancer.
KeywordsPlatelet lymphocyte ratio Ovarian cancer Prognostic marker
- 1.Cancer Research UK (2006) Ovarian cancer incidence statistics. Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/ovary/incidence/index.htm
- 2.Horner MJ, Ries LAG, Krapcho M et al (eds) (2009) SEER cancer statistics review, 1975–2006. Available from: http://seer.cancer.gov/csr/1975_2006/
- 22.Menczer J, Schejter E, Geva D et al (1998) Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 19:82–84Google Scholar
- 28.Ong SL, Garcea G, Thomasset SC et al (2008) Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature. HPB (Oxford) 10:446–458Google Scholar
- 29.Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxelcisplatin chemotherapy: a prospective study. BMC Cancer 10:50PubMedCrossRefGoogle Scholar